In this Friday, May 24, 2019 photo a vendor bags psilocybin mushrooms at a pop-up cannabis market in Los Angeles.ATAI Life Sciences closed a $125 million Series C round, marking the biggest funding round to date in the psychedelics space.
ATAI invests in and acquires companies looking to develop medicines for mental-health conditions from psychedelics like psilocybin, arketamine, and ibogaine. The round announced Monday came from investors including Thiel, Galaxy, Falcon Edge Capital, Catalio Capital Management, and ATAI founder Christian Angermayer's family office Apeiron Investment Group.The CEO of a $1.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
wow